Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review highlights various alternative and complementary treatments for androgenic alopecia, noting that while only two FDA-approved options exist, increased awareness among dermatologists of supportive evidence for other therapies may better inform patient education.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

This review examines mesotherapy for local fat reduction, detailing its mechanisms, safety concerns, and the need for research toward FDA-approved uses, but reports no new clinical findings.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This review discusses two FDA-approved drugs for androgenetic alopecia, finasteride and minoxidil, and reports no new research findings.

This study identified nine compounds that activate Wnt signaling, with aminoacridine and proflavine especially promoting hair and nail regeneration in mouse models, highlighting new therapeutic candidates from existing FDA-approved and natural compounds.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

This review highlights the clinical usefulness of bimatoprost in lowering intraocular pressure for glaucoma patients and its promising results in promoting hair growth for conditions like alopecia, with research also exploring potential new applications and delivery systems.

This paper discusses the introduction and advantages of an Insurance-Based Billing Model for scalp cooling devices in the USA, which can enhance access to this treatment for reducing chemotherapy-induced alopecia, particularly benefiting underserved and disadvantaged populations.

In this review, researchers introduced clinically tunable siRNA delivery systems for hair loss treatment, discussing design principles and analyzing relevant clinical trials to propose a framework for optimizing siRNA delivery in a clinical context.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

This study developed a method using HPLC with UV-DAD and ESI-MS detection to identify prohibited substances like minoxidil and hormones in cosmetic products advertised online for hair loss and skin conditions.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

This study reviewed various lipolytic agents for reducing submental fat and highlighted that while deoxycholic acid is FDA-approved, other compounds like phosphatidylcholine with deoxycholate lack cosmetic approval due to safety concerns. Understanding these agents' mechanisms and anatomy is crucial for safe fat reduction applications.

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

This review outlines current treatments for androgenetic alopecia, highlighting the efficacy and side effects of FDA-approved options like minoxidil and finasteride, and emphasizes the necessity of long-term use and careful patient collaboration to avoid adverse reactions.

This review discusses the potential of using high-throughput and high-content screening methods for drug repositioning in rare diseases and reports no new results.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

This study investigated different centrifugation systems and found that low-speed protocols and certified centrifuges produced better-quality platelet-rich fibrin and recommended using FDA-approved glass tubes for safe and effective regenerative outcomes.

This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.

This review discusses the epidemiology, pathophysiology, diagnosis, and management of male androgenetic alopecia, noting that combination treatments, including FDA-approved and emerging therapies, may improve outcomes without added side effects.

In this study, the researchers performed a comparative analysis of drug-target interaction data from multiple databases to refine drug repurposing strategies, revealing potential associations between drug characteristics and therapeutic groups, and predicting repositioning opportunities for FDA-approved drugs across major cancer types.